- A-Z Publications
- Journal of Endocrinology, Metabolism and Diabetes in South Africa
- Previous Issues
- Volume 14, Issue 1, 2009
Journal of Endocrinology, Metabolism and Diabetes in South Africa - Volume 14, Issue 1, 2009
Volume 14, Issue 1, 2009
Author Stephen HoughSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14 (2009)More Less
In the previous issue of the Journal, our readers were informed that SEMDSA had decided, after much deliberation and debate, to sever its decade-long ties with the South African Medical Association, that the Health and Medical Publishing Group was to be replaced with a private publishing house, Medpharm Publications, and that it was now "time to move on..."
Author Roy ShiresSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14 (2009)More Less
The forthcoming SEMDSA congress promises to be a memorable academic event. Not only do we have an excellent faculty of eminent invited speakers attending, but have also had an enthusiastic response from local scientists based on the large number of abstracts received.
Author Derick RaalSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14 (2009)More Less
The inaugural meeting of the Lipid and Atherosclerosis Society of Southern Africa (LASSA) was held in Johannesburg in September 1989 and was attended by approximately 100 delegates. LASSA was established by a small group of individuals led by Harry Seftel. The aim was to bring together researchers in many different disciplines who were contributing to, or could contribute, to knowledge in the field of lipidology.
Author F.J. RaalSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14, pp 9 –12 (2009)More Less
Atherosclerosis begins in childhood. Not uncommonly, the first presentation of atherosclerosis is sudden cardiac death. It therefore makes sense that risk-factor modification to prevent the development or delay the onset of atherosclerosis needs to begin early in life. Dietary intervention is the key component for the primary prevention of hyperlipidaemia. However, if diet and lifestyle fail to correct hyperlipidaemia, drug therapy may have to be considered. All children and adolescents with high-risk lipid disorders such as familial hypercholesterolaemia (FH), those with diabetes mellitus or other cardiovascular disease risk factors or with a family history of premature coronary artery disease should be considered for lipid-lowering therapy if diet and lifestyle intervention are ineffective. There are now numerous studies that have documented the safety and efficacy of statin therapy in both children and young adults. Based on these studies, it is now recommended that statin therapy be initiated in all male FH children from the age of ten years and at the onset of menses in females with FH. The initiation of statin therapy could be considered even earlier in FH children at high risk.
Source: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14, pp 13 –16 (2009)More Less
Background : Despite increased awareness of risk factors for coronary artery disease and randomized trial data supporting comprehensive diabetic care, these risk factors continue to be largely ignored in patients with type 2 diabetes mellitus.
Objective : Cross-sectional study to determine the level of control in patients with type 2 diabetes in tertiary diabetes clinics.
Methods : Patient demographic, diabetes and cardiovascular disease related (CVD) data was collected from 150 (F:M; 98:52) randomly selected patients with type 2 diabetes mellitus attending the diabetes clinics at the three academic teaching hospitals served by the University of the Witwatersrand. Blood pressure, height, weight, body mass index and waist circumference were measured. Glycated haemoglobin and fasting serum lipid levels were obtained from patient records. Black patients contributed 68%, White 12, 7%, Indian 10, 7% and Coloured 8, 7%.
Results : Mean HbA1c for the whole cohort was 8, 7%. Obesity was present in 37, 3%, hypercholesterolaemia in 29, 3% and hypertriglyceridaemia in 45, 3%. Waist circumference was ≥ 80 cm in 98% of the females and ≥ 94 cm in 69% of the males. 127 patients out of 150 (85%) were hypertensive and 74% of these had a systolic blood pressure ≥ 130 mmHg and 84% a diastolic blood pressure ≥ 80 mmHg. 43% of the patients did minimal exercise, 6% smoked and only 51% were on aspirin.
Conclusion : Comprehensive diabetic care is still largely lacking despite clinical trial data documenting improved outcomes associated not only with glycaemic control but also with use of antihypertensive, lipid lowering and anti-platelet therapy.
Source: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14, pp 17 –19 (2009)More Less
In patients with pheochromocytomas it is well known that different factors can precipitate an acute pheochromocytoma crisis. Our patient presented with a vesicular skin rash and respiratory distress suggestive of disseminated varicella zoster for which he was treated with steroids and acyclovir. Two days later hypertension was noted for the first time.
Scientific Programme 44th Congress of the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) : abstractsSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14, pp 21 –46 (2009)More Less
Scientific programme 9th Congress of the Lipid and Atherosclerosis Society of Southern Africa (LASSA) : abstractsSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14, pp 47 –51 (2009)More Less
Author Naomi (Dinky) LevittSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14 (2009)More Less
Although there is a lack of accurate information on the number of people living with diabetes in South Africa (estimates are of approximately 2 million), it poses a major challenge to our society. Diabetes is the seventh most common cause of death; it also accounts for the majority of non traumatic amputations, is a prominent contributor to end stage renal disease and blindness, and is present in many people with acute strokes and myocardial infarction.
SEMDSA Guidelines for Diagnosis and Management of Type 2 Diabetes Mellitus for Primary Health Care - 2009 : SEMDSA guidelinesSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14, pp 55 –58 (2009)More Less
Position paper on the indications for the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis : NOFSA position paperAuthor S.L. BrownSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14, pp 61 –62 (2009)More Less
Parathyroid hormone (PTH) is a peptide hormone secreted by the parathyroid glands which, amongst many varied physiological effects, serves to maintain normal serum calcium levels. In fulfilling this function, the hormone interacts with its receptors in a number of tissues, including bone. One effect in bone is to stimulate preosteoblast formation and differentiation to mature functional osteoblasts and to prevent their apoptosis. Cytokines subsequently released by the osteoblasts then stimulate osteoclastic activity, bone breakdown and release of calcium into the circulation. Continued high level exposure of bone to PTH will result in eventual bone loss, but intermittent exposure will have an anabolic effect - fact which makes this peptide useful as a potent treatment for osteoporosis. Teriparatide is a 34 amino acid peptide which mimics the physiological effects of PTH and is registered in South Africa for the treatment of established osteoporosis with or without vertebral fractures in post menopausal women and in men. The intact human recombinant molecule PTH (1-84) is not available in South Africa and will not therefore be included in this discussion.
Lilly SA announces appointment of first local MD in over a decade and introduces Diabetes Conversations at this year's SEMDSA / DESSA Congress : press releaseSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 14 (2009)More Less
Jacques Blaauw, 37, has been appointed as Lilly's new managing director for South Africa and Sub Saharan Africa. He is the first local MD in over 12 years. Jacques takes over from American Jim Ringer who has been heading Lilly South Africa for the past three years. Ringer returned to Lilly's global head office in Indianapolis, Indiana.